Phototherapy for Neonatal Hyperbilirubinemia
Customize your policy alerts
Sign up for Arizona Complete Health Policy CP.MP.150 alerts
Get alerted when Policy CP.MP.150 changes without checking for updates manually.
Monitor payer policy activity
Medical necessity criteria and coverage stance for home and inpatient phototherapy and exchange transfusion for neonatal hyperbilirubinemia, directed to clinicians and payers managing newborns ≥38 weeks gestation and related services.
Updated Criteria I.J.1. wording from glucose-6-phosphate dehydrogenase (G6PD) to G6PD deficiency.
Rearranged verbiage regarding infants ≥ 38 weeks gestation in Criteria I. and I.A., and removed 'Term' verbiage in Criteria I.B.
Clarified that extenuating circumstances for inpatient phototherapy can include lack of expected compliance with therapy at home.
Coverage Criteria for Phototherapy and Exchange Transfusion
Home Phototherapy Eligibility
Covered when ALL of the following are met:
Home phototherapy criteria
- Risk factor exclusions (none should be present): Isoimmune hemolytic disease (e.g., positive direct antiglobulin test), G6PD deficiency, or other hemolytic disease; hypoxic ischemia encephalopathy/asphyxia; temperature instability; sepsis; acidosis; albumin < 3.0 g/dL if measured; birth weight < 2500 g; significant cephalohematoma or bruising; weight loss ≥ 10%; elevated direct-reacting/conjugated bilirubin; jaundice appearing in first 24 hours of life; laboratory or clinical evidence of hypothyroidism; significant clinical instability in the previous 24 hours; clinical history of a parent or sibling requiring phototherapy or exchange transfusion; exclusive breastfeeding or chestfeeding with suboptimal intake; Down syndrome; macrosomic infant of a diabetic mother
None of these risk factors may be present for home phototherapy eligibility.
TSB must be within these age-based limits for home phototherapy.
Inpatient Phototherapy / Exchange Transfusion
Inpatient phototherapy or exchange transfusion is covered when:
Meeting any one of these conditions supports inpatient treatment or exchange transfusion.
ICD-10 diagnosis code lists previously included in this policy have been removed. The policy no longer lists specific ICD-10 codes for neonatal hyperbilirubinemia; coverage determinations should be made using the clinical criteria and requirements stated in this document rather than diagnosis code lists.
This clinical policy is a guide to medical necessity and coverage decisions and was developed by qualified clinicians based on available evidence and standards of practice. Coverage determinations remain subject to the member's plan documents and applicable state and federal laws. Where state Medicaid coverage provisions conflict with this clinical policy, the state Medicaid provisions take precedence.
Home phototherapy is appropriate only when the infant meets all eligibility criteria listed in this policy. Home phototherapy is not appropriate when the infant does not satisfy the listed criteria (for example, gestational age < 38 weeks, clinical instability, listed risk factors present, no LED device available, inability to obtain daily TSB measurements, or lack of timely follow-up) or when the infant's Total Serum Bilirubin (TSB) is >1 mg/dL above the AAP phototherapy treatment threshold as identified in the AAP bili risk calculator; such situations warrant inpatient phototherapy or other escalation of care.
Coding and Thresholds
Provider Responsibilities, Prior Authorization, and Documentation
Triggers for denial of home phototherapy
Inpatient phototherapy should be used (home phototherapy denied) when the infant does not meet the criteria for home phototherapy, including any of the risk factors or TSB thresholds listed in the policy. Specifically, home phototherapy is not appropriate and may be denied when: the infant is < 38 weeks gestation; age < 48 hours; feeding poorly or clinically unstable; lactation support has not been offered when breastfeeding/chestfeeding; no primary care provider is willing to manage home care with timely follow-up; prior phototherapy has already been given; an LED-based device cannot be made available in the home without delay; or the infant has any listed risk factors (e.g., isoimmune hemolytic disease, G6PD deficiency, HIE/asphyxia, temperature instability, sepsis, acidosis, albumin <3.0 g/dL, birth weight <2500 g, significant cephalohematoma or bruising, weight loss ≥10%, elevated direct/conjugated bilirubin, jaundice in first 24 hours, hypothyroidism, recent clinical instability, family history of severe neonatal jaundice or exchange transfusion, exclusive breastfeeding with suboptimal intake, Down syndrome, macrosomic infant of a diabetic mother). Home phototherapy will also be denied if the measured total serum bilirubin (TSB) exceeds the acceptable levels for home phototherapy (see Table 1) or is >1 mg/dL above the AAP phototherapy treatment threshold per the AAP risk calculator.
- Infant < 38 weeks gestation
- Infant < 48 hours old
- Feeding poorly or clinically unstable
- Lactation support not offered when breastfeeding/chestfeeding
- No PCP willing to manage home care with 12–24 hour follow-up
- Prior phototherapy given
- No LED-based device available in the home without delay
- Any listed risk factor present (see policy list)
- TSB exceeds Table 1 limits for age or is >1 mg/dL above AAP treatment threshold
Clinical documentation responsibility
Providers must document in the medical record the clinical findings and rationale supporting home phototherapy or inpatient treatment decisions and maintain evidence of adherence to the policy criteria. Providers are expected to exercise professional medical judgment and ensure documentation includes gestational age, infant age (hours), feeding status, lactation support offered (if applicable), availability of LED-based device in the home, prior phototherapy history, daily TSB monitoring plan, presence/absence of listed risk factors, and primary care follow-up arrangements.
- Document gestational age (≥38 weeks required for home phototherapy)
- Document infant age (≥48 hours required)
- Document feeding status and clinical stability
- Document lactation support offered if breastfeeding/chestfeeding
- Document availability of LED-based phototherapy device in the home
- Document plan for daily TSB measurement and follow-up within 12–24 hours
- Document primary care provider willingness to manage home care and follow-up
- Retain documentation of decision if inpatient phototherapy or exchange transfusion is used
Background and Scope
Neonatal hyperbilirubinemia is common. Rising total serum bilirubin (TSB) can lead to acute bilirubin-induced neurologic dysfunction (BIND) and, when severe, permanent injury (kernicterus). Phototherapy, preferably using LED devices in the blue-green spectrum (approximately 460–490 nm) with adequate irradiance, is the first-line treatment to reduce TSB. For otherwise-healthy infants who meet the policy's eligibility criteria, phototherapy may be delivered in the home setting with close follow-up and daily TSB monitoring to reduce the need for readmission; infants who do not meet criteria or who have TSB levels exceeding treatment thresholds should receive inpatient phototherapy or exchange transfusion per recognized decision support tools.
Definitions and Phototherapy Types
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.